Showing results (191-200 of 214) with videos related to
Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid TumorsDiwakar Davar, Roberta Zappasodi, Hong Wang, et al.BJU International|February 17, 2023
Urine supernatant reveals a signature that predicts survival in clear-cell renal cell carcinomaJorge Daza, Bérengère Salomé, Kennedy Okhawere, et al.Gastroenterology|February 17, 2026
Single-Cell Analysis of Chemotherapy-induced Remodeling Reveals CD276-driven Basal-like Chemoresistance in Pancreatic CancerYao Zhang, Yanhua Du, Jiaxin Wang, et al.Toxics|November 24, 2022
Prenatal Metal Exposures and Associations with Kidney Injury Biomarkers in ChildrenMaria D Politis, Meizhen Yao, Chris Gennings, et al.Nature Medicine|May 1, 2019
Rational design of anti-GITR-based combination immunotherapyRoberta Zappasodi, Cynthia Sirard, Yanyun Li, et al.Cancers|March 11, 2023
Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third RemissionBeryl L Manning-Geist, Sacha Gnjatic, Carol Aghajanian, et al.Nature Communications|April 2, 2022
Single-cell and spatial analysis reveal interaction of FAP<sup>+</sup> fibroblasts and SPP1<sup>+</sup> macrophages in colorectal cancerJingjing Qi, Hongxiang Sun, Yao Zhang, et al.Cancer Research Communications|March 27, 2023
A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent GlioblastomaDaniel Chiu, Jingjing Qi, Tin Htwe Thin, et al.Journal of Ethnopharmacology|November 11, 2021
Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection: A multicentre, double-blind, and randomised controlled trialYuqin Chen, Chunli Liu, Tingping Wang, et al.Proceedings of the National Academy of Sciences of the United States of America|January 21, 2026
Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrugLaura Antonucci, Kosuke Watari, Yechen Feng, et al.Pageof 22